Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx
<p>Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recentl...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852026642042454016 |
|---|---|
| author | Hu Feng (6641357) |
| author2 | Shasha Bi (19675897) Shanshan Sun (275585) Hongbo Yang (267562) Haoxing Zhou (19675900) Jingjing Mao (175629) Na Li (6550) Fujun Yang (8151096) |
| author2_role | author author author author author author author |
| author_facet | Hu Feng (6641357) Shasha Bi (19675897) Shanshan Sun (275585) Hongbo Yang (267562) Haoxing Zhou (19675900) Jingjing Mao (175629) Na Li (6550) Fujun Yang (8151096) |
| author_role | author |
| dc.creator.none.fl_str_mv | Hu Feng (6641357) Shasha Bi (19675897) Shanshan Sun (275585) Hongbo Yang (267562) Haoxing Zhou (19675900) Jingjing Mao (175629) Na Li (6550) Fujun Yang (8151096) |
| dc.date.none.fl_str_mv | 2024-09-16T04:01:24Z |
| dc.identifier.none.fl_str_mv | 10.3389/fonc.2024.1367140.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_Complete_response_to_disitamab_vedotin_in_HER2-low_metastatic_endometrial_carcinoma_a_case_report_and_review_of_the_literature_docx/27022903 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Oncology and Carcinogenesis not elsewhere classified endometrial cancer HER2-low ADCS RC48 recurrent metastasis complete response |
| dc.title.none.fl_str_mv | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recently, are limited. Antibody drug conjugates (ADCs) represent innovative strategies in cancer treatment; however, there are less investigations regarding their efficacy in EC. This report describes an EC case with low human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) expression score (IHC 2+) that experienced recurrent metastasis in the abdominal and peritoneal following post-surgical chemotherapy and radiotherapy. Subsequently, the commencement of HER2-targeted ADC, disitamab vedotin (RC48; 2.5 mg/kg), administered intravenously every two weeks, was initiated. The tumor lesions shrunk markedly after three cycles of treatment and disappeared by the completion of ten cycles of therapy. The patient is still in remission at present. The current findings imply the potential efficacy of HER2-targeted ADCs for patients with HER2-low metastatic EC.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_79c00a67ad2fd485cb263e2c7d1ff3ca |
| identifier_str_mv | 10.3389/fonc.2024.1367140.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/27022903 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docxHu Feng (6641357)Shasha Bi (19675897)Shanshan Sun (275585)Hongbo Yang (267562)Haoxing Zhou (19675900)Jingjing Mao (175629)Na Li (6550)Fujun Yang (8151096)Oncology and Carcinogenesis not elsewhere classifiedendometrial cancerHER2-lowADCSRC48recurrent metastasiscomplete response<p>Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recently, are limited. Antibody drug conjugates (ADCs) represent innovative strategies in cancer treatment; however, there are less investigations regarding their efficacy in EC. This report describes an EC case with low human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) expression score (IHC 2+) that experienced recurrent metastasis in the abdominal and peritoneal following post-surgical chemotherapy and radiotherapy. Subsequently, the commencement of HER2-targeted ADC, disitamab vedotin (RC48; 2.5 mg/kg), administered intravenously every two weeks, was initiated. The tumor lesions shrunk markedly after three cycles of treatment and disappeared by the completion of ten cycles of therapy. The patient is still in remission at present. The current findings imply the potential efficacy of HER2-targeted ADCs for patients with HER2-low metastatic EC.</p>2024-09-16T04:01:24ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fonc.2024.1367140.s001https://figshare.com/articles/dataset/Table_1_Complete_response_to_disitamab_vedotin_in_HER2-low_metastatic_endometrial_carcinoma_a_case_report_and_review_of_the_literature_docx/27022903CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/270229032024-09-16T04:01:24Z |
| spellingShingle | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx Hu Feng (6641357) Oncology and Carcinogenesis not elsewhere classified endometrial cancer HER2-low ADCS RC48 recurrent metastasis complete response |
| status_str | publishedVersion |
| title | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| title_full | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| title_fullStr | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| title_full_unstemmed | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| title_short | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| title_sort | Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx |
| topic | Oncology and Carcinogenesis not elsewhere classified endometrial cancer HER2-low ADCS RC48 recurrent metastasis complete response |